As of September 30, 2025, cash and cash equivalents were $135.2 million. Net cash usage was approximately $14 million in the third quarter 2025, representing a 77% improvement from net cash usage of approximately $63 million in the second quarter 2025. Based on its current operating plan and projected product revenues, Phathom believes these resources will be sufficient to fund operations and achieve operating profitability in 2026, excluding stock-based compensation, without the need for additional equity financing.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals’ EoE Study: A Potential Game-Changer?
- Phathom Pharmaceuticals’ Vonoprazan Pregnancy Study: A Market Game Changer?
- Phathom Pharmaceuticals Publishes Phase 3 Trial Results
- Phathom Pharmaceuticals Appoints New Chief Financial Officer
- Phathom appoints Sanjeev Narula as chief financial, business officer